Oxford BioMedica PLC
LSE:OXB
Intrinsic Value
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. [ Read More ]
The intrinsic value of one
OXB
stock under the Base Case scenario is
311.35
GBX.
Compared to the current market price of 218.1 GBX,
Oxford BioMedica PLC
is
Undervalued by 30%.
Oxford BioMedica PLC's market capitalization is 210.5m GBX.
OXB stock price is 218.1 GBX.
OXB stock price (218.1 GBX) is 30% less than its Intrinsic Value (311.35 GBX).
OXB stock price (218.1 GBX) is 64% less than its Relative Value (613.39 GBX). Open Relative Valuation
OXB has upside potential of 95% compared to the average analyst price target.
Open Wall St Estimates
OXB's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
OXB's Revenue has dropped by 5% over the past 12 months.
OXB has negative Net Debt. This means that the company has more cash and short-term investments (129m GBP) than debt (109m GBP).
OXB's long-term assets (401m GBP) exceed its long-term liabilties (229m GBP).
OXB's Revenue has been growing by an exceptional 22% per year for the last 3 years.
OXB's ROE (Return on Equity) has significantly decreased in the last 3 years from -7% to -31%, and is approaching profitability.
OXB's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -4% to -28%, and is approaching profitability.
OXB's D/E (Debt to Equity) is very low and is equal to 0.64.
OXB has negative Operating Income for the last twelve months.
OXB has negative Net Income for the last twelve months.
OXB's ROE (Return on Equity) for the past 12 months is negative and is equal to -31%.
OXB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -28%.
OXB has positive Gross Profit for the last twelve months.
OXB has negative three-year average ROIC (Return on Invested Capital): -6%. The company is not efficient at using invested capital to generate operating income.
OXB has negative three-year average ROE (Return on Equity): -8%. The company is not efficient at transforming stockholders' equity into net income.
OXB has negative Free Cash Flow for the last twelve months.
OXB's short-term assets (178m GBP) exceed its short-term liabilties (54m GBP).
OXB's Altman Z-Score is very low and is equal to -0.24.
OXB doesn't generate enough operating income (-84m GBP) to safely cover interest payments on its debt (11m GBP).
Valuation Backtest
Oxford BioMedica PLC
Run backtest to discover the historical profit from buying and selling
OXB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Oxford BioMedica PLC
Balance Sheet Decomposition
Oxford BioMedica PLC
| Current Assets | 177.7m |
| Cash & Short-Term Investments | 129.4m |
| Receivables | 29.5m |
| Other Current Assets | 18.7m |
| Non-Current Assets | 223.4m |
| PP&E | 120.6m |
| Intangibles | 97.9m |
| Other Non-Current Assets | 4.9m |
| Current Liabilities | 53.5m |
| Accounts Payable | 9.2m |
| Accrued Liabilities | 17m |
| Other Current Liabilities | 27.3m |
| Non-Current Liabilities | 175.4m |
| Long-Term Debt | 109.5m |
| Other Non-Current Liabilities | 65.9m |
Earnings Waterfall
Oxford BioMedica PLC
|
Revenue
|
119m
GBP
|
|
Cost of Revenue
|
-64m
GBP
|
|
Gross Profit
|
55m
GBP
|
|
Operating Expenses
|
-138.7m
GBP
|
|
Operating Income
|
-83.7m
GBP
|
|
Other Expenses
|
22m
GBP
|
|
Net Income
|
-61.6m
GBP
|
Free Cash Flow Analysis
Oxford BioMedica PLC
OXB Profitability Score
Profitability Due Diligence
Oxford BioMedica PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Oxford BioMedica PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
OXB Solvency Score
Solvency Due Diligence
Oxford BioMedica PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Oxford BioMedica PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OXB Price Targets Summary
Oxford BioMedica PLC
According to Wall Street analysts, the average 1-year price target for
OXB
is 425.47 GBX
with a low forecast of 181.8 GBX and a high forecast of 777 GBX.
Shareholder Return
OXB Price
Oxford BioMedica PLC
| Average Annual Return | 0.94% |
| Standard Deviation of Annual Returns | 47.22% |
| Max Drawdown | -90% |
| Market Capitalization | 210.5m GBX |
| Shares Outstanding | 100 257 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Oxford BioMedica PLC
Country
Industry
Market Cap
Dividend Yield
Description
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Contact
IPO
Employees
Officers
The intrinsic value of one
OXB
stock under the Base Case scenario is
311.35
GBX.
Compared to the current market price of 218.1 GBX,
Oxford BioMedica PLC
is
Undervalued by 30%.
You don't have any saved screeners yet
